Psoriasis News and Research

Latest Psoriasis News and Research

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Anacor Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

11 Feb 2011

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

Researchers identify immune cell population that acts as body's border patrol with the outside world

So-called barrier sites -- the skin, gut, lung - limit the inner body's exposure to allergens, pollutants, viruses, bacteria, and parasites. Understanding how the immune system works in these external surfaces has implications for understanding such inflammatory diseases as asthma, psoriasis, IBD, and food allergies, all of which occur at the body's barriers.

8 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

27 Jan 2011

DMP1 protein prevents endothelial cells to respond to VEGF

A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.

27 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

26 Jan 2011

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

26 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Boehringer Ingelheim to acquire Amgen's Fremont California development and manufacturing facility

Amgen Inc. and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility.

19 Jan 2011

Manhattan enters settlement and release agreement with Nordic and H Pharmaceuticals

Manhattan Pharmaceuticals, Inc. announced that on January 4, 2011, the company entered into a settlement and release agreement with Nordic Biotech Fund II K/S and H Pharmaceuticals K/S. Manhattan Pharmaceuticals and Nordic are partners in the H Pharmaceuticals joint venture for the development and commercialization of Hedrin®, a non-pesticide treatment for head lice.

10 Jan 2011

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).

10 Jan 2011

Psoriasis News and Research

Latest Psoriasis News and Research

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

NMS Labs launches unique test for Methotrexate

Researchers identify immune cell population that acts as body's border patrol with the outside world

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

DMP1 protein prevents endothelial cells to respond to VEGF

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Boehringer Ingelheim to acquire Amgen's Fremont California development and manufacturing facility

Manhattan enters settlement and release agreement with Nordic and H Pharmaceuticals

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Psoriasis News and Research

Latest Psoriasis News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in